A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
Home Therapies Neural Stimulation Archive for category "Brain Stimulation"
formats

Medtronic Implants Activa® PC+S DBS IPG in US

Medtronic today announced the first US implant of the novel Activa® PC+S deep brain stimulation (DBS) system that, for the first time, enables the sensing and recording of select brain activity while simultaneously providing targeted DBS therapy. According to the press release: MINNEAPOLIS – December 5, 2013 – Medtronic, Inc. (NYSE: MDT) today announced the

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Medtronic Implants Activa® PC+S DBS IPG in US  comments 
formats

Medtronic Reports CRM AIMD Sales Trend Showing Stabilization + Strong Earnings from Neuromodulation AIMDs

Medtronic released today its earning reports for the second quarter of fiscal year 2014, which ended October 25, 2013. Medtronic states in the press release: “Second quarter revenue from Implantable Cardioverter Defibrillators (ICDs) was $713 million, an increase of 4 percent on a constant currency basis in a market that continues to show a trend

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Medtronic Reports CRM AIMD Sales Trend Showing Stabilization + Strong Earnings from Neuromodulation AIMDs  comments 
formats

NeuroPace Receives FDA PMA Approval for for the RNS System to Treat Refractory Partial Epilepsy

NeuroPace is a privately-held company in Mountain View, CA. Their RNS® implantable stimulator, along with depth leads and cortical strip leads are designed for the treatment of medically refractory partial epilepsy. On November 14, 2013, NeuroPace has now received FDA pre-market approval for the NeuroPace RNS System as a treatment for adults with partial onset

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on NeuroPace Receives FDA PMA Approval for for the RNS System to Treat Refractory Partial Epilepsy  comments 
formats

Medtronic Implants first Activa® PC+S DBS IPG Capable of Sensing and Recording Brain Activity While Delivering Therapy

Medtronic today announced the first implant of the novel Activa® PC+S deep brain stimulation (DBS) system that, for the first time, enables the sensing and recording of select brain activity while simultaneously providing targeted DBS therapy. According to the press release: This initiates research on how the brain responds to the therapy and could yield insights that

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Medtronic Implants first Activa® PC+S DBS IPG Capable of Sensing and Recording Brain Activity While Delivering Therapy  comments 
formats

NeuroPace Raises $18M of Planned $50M

NeuroPace is a privately-held company in Mountain View, CA. Their RNS® implantable stimulator, along with depth leads and cortical strip leads are designed for the treatment of medically refractory partial epilepsy. Unlike Cyberonics’ VNS IPGs, the RNS neurostimulator is designed to detect abnormal electrical activity in the brain and respond by delivering electrical stimulation to

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on NeuroPace Raises $18M of Planned $50M  comments 
formats

Aleva Neurotherapeutic’s Ultra-Flexible Electrode Arrays for DBS

Aleva Neurotherapeutics is a spinoff of the Swiss Federal Institute of Technology (EPFL) Microsystems Laboratory.   Aleva is developing unique microfabricated devices to more specifically target deep-brain stimulation. kurtzweilai.net recently published an interesting blog about the technology.  From the post: “Miniature, ultra-flexible electrodes could be the answer to more successful treatment for Parkinson’s diseases, according to Professor

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Aleva Neurotherapeutic’s Ultra-Flexible Electrode Arrays for DBS  comments 
formats

Boston Scientific Begins Patient Enrollment in U.S. Clinical Trial of Vercise™ DBS for Parkinson’s Disease, Presents EU Data

Boston Scientific announced today the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. INTREPID is a prospective, multi-center, double-blinded, randomized, controlled study to evaluate the safety and effectiveness of motor function and overall quality of life in patients with the Vercise DBS System for the treatment of Parkinson’s disease. 

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Boston Scientific Begins Patient Enrollment in U.S. Clinical Trial of Vercise™ DBS for Parkinson’s Disease, Presents EU Data  comments 
formats

St. Jude’s DBS Systems First to Receive CE Mark for Both Primary and Secondary Dystonia

St. Jude Medical announced CE Mark approval of its Brio™, Libra™ and LibraXP™ deep brain stimulation (DBS) systems for managing the symptoms of intractable primary and secondary dystonia, a neurological movement disorder that causes a person’s muscles to contract and involuntarily spasm, reducing the ability to control movement. This approval represents the first by a

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on St. Jude’s DBS Systems First to Receive CE Mark for Both Primary and Secondary Dystonia  comments 
formats

Medtronic Introduces First Neuromodulation Systems Compatible with Full-Body MRI

Medtronic has introduced in Europe the first and only implantable neurostimulation systems indicated for use in the treatment of chronic back and/or leg pain that are designed for full-body Magnetic Resonance Imaging (MRI) scans under specific conditions.  Medtronic SureScan neurostimulation systems include enhancements to existing devices as well as specially designed leads to reduce or

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Medtronic Introduces First Neuromodulation Systems Compatible with Full-Body MRI  comments 
formats

Functional Neuromodulation Ltd. Starts Study using DBS of the Fornix (DBS-f) for Mild Alzheimer’s

Toronto-based Functional Neuromodulation announced that it implanted the first U.S. Alzheimer’s patient in the “ADvance Study” with a deep brain stimulation (DBS) system meant to improve cognitive performance. ADvance will evaluate the safety and potential clinical benefit of DBS of the fornix (DBS-f), a major inflow and output pathway in the brain’s memory circuit, for

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Functional Neuromodulation Ltd. Starts Study using DBS of the Fornix (DBS-f) for Mild Alzheimer’s  comments 
formats

Boston Scientific Receives CE Mark of Vercise™ Deep Brain Stimulation System

Boston Scientific Corporation received CE Mark approval for use of its Vercise™ Deep Brain Stimulation (DBS) System for the treatment of Parkinson’s disease. The Vercise DBS System is the first and only commercially available DBS system to incorporate multiple independent current control, which is designed to selectively stimulate targeted areas in the brain. This system is

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Boston Scientific Receives CE Mark of Vercise™ Deep Brain Stimulation System  comments 
formats

Monash University in Australia Starts Test of Direct-to-Brain Visual Prosthesis Chips

Engineers from the Monash Vision Group (MVG) have begun trialling the ASICs for a direct-to-brain visual prosthesis that is expected to enter human clinical trials in 2014. The prosthesis will consist of a tiny camera mounted into a pair of glasses, which acts as the retina; a pocket processor, which takes the electronic information from

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Monash University in Australia Starts Test of Direct-to-Brain Visual Prosthesis Chips  comments 
formats

John Hopkins Researcher Develops New Early-Warning Seizures Detector with Low False-Positive Rate

Johns Hopkins’ Sridevi V. Sarma, an assistant professor of biomedical engineering, has devised new seizure detection software that, in early testing, significantly cuts the number of unneeded brain-stimulation therapy that an epilepsy patient would receive. According to Sarma, “These devices use algorithms—a series of mathematical steps—to figure out when to administer the treatment,” Sarma said. “They’re

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on John Hopkins Researcher Develops New Early-Warning Seizures Detector with Low False-Positive Rate  comments 
formats

Neuromed’s TIME Battery- and RF-Powered Totally Implantable Multichannel Spinal Cord Stimulator (ca. 1988)

Neuromed was formed in 1980 with an initial capitalization of $150,000 by Bill Borkan through money obtained when Borkan`s parents took out a second mortgage on their home. Borkan’s desire to help his sister, Jennie, a cerebral palsy patient, got him started in neurostimulation technology. In the next few years, Neuromed developed and marketed a

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Neuromed’s TIME Battery- and RF-Powered Totally Implantable Multichannel Spinal Cord Stimulator (ca. 1988)  comments 
formats

St. Jude’s DBS Study Confirms Benefit of Constant Current System for Parkinson’s Disease

Image Credit: St. Jude Medical Today St. Jude announced that its first controlled study of Deep Brain Stimulation (DBS) confirms benefit of constant current system for patients with Parkinson’s Disease. Results were published online today by The Lancet Neurology journal. The aim of the study was to evaluate the Libra(TM) and LibraXP(TM) DBS constant current systems

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on St. Jude’s DBS Study Confirms Benefit of Constant Current System for Parkinson’s Disease  comments